Abbott initiates new intravascular lithotripsy clinical trial to improve outcomes in patients with coronary artery disease

Coronary artery disease (cad) is the most common heart disease and most frequent cause of death in the u.s., with over 20 million adults affected by this condition abbott's investigational coronary intravascular lithotripsy (ivl) system offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages abbott offers a comprehensive vascular portfolio of technologies designed to assess, treat and manage calcium buildup in coronary arteries abbott park, ill., march 24, 2025 /prnewswire/ -- abbott (nyse: abt) today announced that the u.s. food and drug administration (fda) has approved an investigational device exemption (ide) for its coronary intravascular lithotripsy (ivl) system to evaluate the treatment of severe calcification in coronary arteries prior to stenting.
ABT Ratings Summary
ABT Quant Ranking